Overview

TCR-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in nave T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

Status:
RECRUITING

Trial end date:
2030-12-01

Target enrollment:

Participant gender:

Summary

This is a phase I, prospective clinical trial studying the safety and feasibility of providing early memory T-cell DLI. The primary objective is: \- To assess the safety and feasibility of early CD45RA-depleted DLI administration. The secondary objectives are * To assess the safety and feasibility of the addition of blinatumomab in the early post-transplant period in patients with CD19+ malignancy. * To measure and describe the pharmacokinetics of rabbit ATG in HCT recipients on this study.

Phase:

PHASE1

Details

Lead Sponsor:

St. Jude Children's Research Hospital

Treatments:

blinatumomab
Cyclophosphamide
Filgrastim
fludarabine
Melphalan
Mesna
Thiotepa
thymoglobulin